Preparation of branched dextran microspheres of soluble interferonalpha and its activity in vitro and in vivo

Journal of Microbiology and Biotechnology

Volumn 21, Issue 2, 2011, Pages 176-182

  Hua, Hong ^a   Jo, Jeong Rang ^a   Yeon, Ji Hyeon ^b   Hong, Jun Tack ^c   Jung, Kyung Hwan ^b   Yoo, Sun Kyun ^c   Jang, Byeong Churl ^a  

^a Keimyung University School of Medicine   (South Korea)

^b Chungju National University   (South Korea)

^c Joongbu University   (South Korea)

Author keywords

Branched dextran microspheres; Hepg2; Ifn ; Neopterin; P stat 1

Indexed keywords

ALPHA INTERFERON; DEXTRAN GLYCIDYL METHACRYLATE; DRUG VEHICLE; MICROSPHERE; NEOPTERIN; POLYHISTIDINE TAG; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROEMULSION; MICROENCAPSULATION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; DELAYED-ACTION PREPARATIONS; DEXTRANS; DRUG CARRIERS; HEPATOCYTES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MICROSPHERES; PLASMA; PROTEIN BINDING; RATS; SIGNAL TRANSDUCTION; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 79952364861     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1007.07060     Document Type: Article

References (33)

1. Abuchowski, A. A., T. van Es, N. C. Palczuk, and F. F. Davis. 1977. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252: 3578-3581.
2. Beilharz, M. W. 2000. Therapeutic potential for orally administered type 1 interferons. Pharm. Sci. Technol. Today 3: 193-197.
3. Chen, F. M., Z. F. Wu, Q. T. Wang, H. Wu, Y. J. Zhang, X. Nie, and Y. Jin. 2005. Preparation of recombinant human bone morphogenetic protein-2 loaded dextran-based microspheres and their characteristics. Acta Pharmacol. Sin. 26: 1093-1103.
4. Chourasia, M. K. and S. K. Jain. 2004. Polysaccharides for colon targeted drug delivery. Drug Deliv. 11: 129-148.
5. Caliceti, P. and F. M. Veronese. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55: 1261-1277.
6. Franssen, O., L. Vandervennet, P. Roders, and W. E. Hennink. 1999. Degradable dextran hydrogels: Controlled release of a model protein from cylinders and microspheres. J. Control. Release 60: 211-221.
7. Fu, K., D. W. Pack, A. M. Klibanov, and R. Langer. 2000. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 171: 100-106.
8. Goh, K. C., S. J. Haque, and B. R. Williams. 1999. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18: 5601-5608.
9. Heathcote, J. and S. Zeuzem. 2004. Pegylated interferon monotherapy for chronic hepatitis C. Semin. Liver Dis. 24: 39-45.
10. Jung, K.-H., Y. J. Lee, J.-H. Yeon, S. K. Yoo, and B.-C. Jang. 2009. Improvement of soluble recombinant interferon-α expression by methyl α-D-glucopyranoside in araBAD promoter system of Escherichia coli. Biotechnol. Bioprocess Eng. 14: 274-280.
11. Jung, K.-H., Y. S. Park, J.-H. Yeon, S. H. Kim, S. K. Yoo, and B.-C. Jang. 2008. Improving the yield of soluble 6×His-tagged interferon-α via the addition of repressor of the araBAD promoter system in Escherichia coli. Biotechnol. Lett. 30: 1577-1582.
12. Kojima, T., M. Hashida, S. Muranishi, and H. J. Sezaki. 1980. Mitomycin C dextran conjugate: A novel high molecular weight pro-drug of mitomycin C. J. Pharm. Pharmacol. 32: 30-34.
13. Lee, Y. J. and K.-H. Jung. 2007. Modulation of the tendency towards inclusion body formation of recombinant protein by the addition of glucose in the araBAD promoter system of Escherichia coli. J. Microbiol. Biotechnol. 17: 1898-1903.
14. Lim, H. K., S. W. Lee, K. Y. Kang, T. G. Park, and K.-H. Jung. 2002. Sustained release of PEGylated G-CSF from PLGA microsphere. Kor. J. Biotechnol. Bioeng. 17: 33-37.
15. Lu, B., J. F. Feng, and X. C. Yang. 2004. Human recombinant interferon-a2a polybutylcyanoacrylate sustained release lyophilized nanospheres for liver-targeting. J. Sichuan Univ. (Med. Sci. Edi.). 35: 1-4.
16. Matsukawa, Y., S. Nishinarita, T. Horie, M. Moriyama, N. Tanaka, Y. Arakawa, S. Kamei, M. Matsuura, and T. Kojima. 2000. Serum concentration of interferon-alpha: A comparison between once-a-day and twice-a-day administration. Int. J. Clin. Pharmacol. Res. 20: 17-19.
17. Matthews, S. J. and C. McCoy. 2004. Peginterferon alfa-2a: A review of approved and investigational uses. Clin. Ther. 26: 991-1025.
18. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
19. Quiroga, J. A., J. Martin, M. Pardo, and V. Carreño. 1994. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig. Dis. Sci. 39: 2485-2496.
20. Roberts, M. J., M. D. Bentley, and J. M. Harris. 2002. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54: 459-476.
21. Sánchez, A., M. Tobío, L. González, A. Fabra, and M. J. Alonso. 2003. Biodegradable micro- and nanoparticles as longterm delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 18: 221-229.
22. Schmeisser, H., P. Kontsek, D. Esposito, W. Gillette, G. Schreiber, and K. C. Zoon. 2006. Binding characteristics of IFN-alpha subvariants to IFNAR2-EC and influence of the 6- histidine tag. J. Interferon Cytokine Res. 26: 866-876.
23. Shenderova, A., T. G. Burke, and S. P. Schwendeman. 1999. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16: 241-248.
24. Shepherd, J., H. Brodin, C. Cave, N. Waugh, A. Price, and J. Gabbay. 2004. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol. Assess. 8: 1-125.
25. Vandelli, M. A., F. Rivasi, P. Guerra, F. Forni, and R. Arletti. 2001. Gelatin microspheres crosslinked with D,L-glyceraldehydeas a potential drug delivery system: Preparation, characterisation, in vitro and in vivo studies. Int. J. Pharm. 215: 175-184.
26. Vyas, S. P., M. Rawat, A. Rawat, S. Mahor, and P. N. Gupta. 2006. Pegylated protein encapsulated multivesiclar liposomes: A novel approach for sustained release of interferon a. Drug Dev. Ind. Pharm. 32: 699-707.
27. Wang, Y. S., S. Youngster, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss. 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54: 547-570.
28. Yoo, S. K., D. M. Kim, and D. F. Day. 2001. Co-production of dextran and mannitol by Leuconostoc mesenteroides. J. Microbiol. Biotechnol. 11: 880-883.
29. Yoshikawa, Y., Y. Komuta, T. Nishihara, Y. Itoh, H. Yoshikawa, and K. Takada. 1999. Preparation and evaluation of once-a-day injectable microspheres of interferon alpha in rats. J. Drug Target. 6: 449-461.
30. Zhang, Y. M., F. Yang, Y. Q. Yang, F. L. Song, and A. L. Xu. 2008. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: Pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration. Acta Pharmacol. Sin. 29: 1370-1375.
31. Robyt, J. F. and Ecklund, S. H. 1983. Relative, quantitative effect of acceptors in the reaction of Leuconostoc mesenteroides dextransucrase. Carbohydr. Res. 121: 279-286.
32. Robyt, J. F. 1986. Encyclopedia of Polymer Science and Technology, pp. 752-767, 4th Ed. John Wiley & Sons, New York, USA
33. Mehvar, R. 2000. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 69: 1-25.